Content Type: Article

  • The Final FDII Regulations: Sales of Products to Foreign Customers for Foreign Use

    The Final FDII Regulations: Sales of Products to Foreign Customers for Foreign Use

    ARTICLE

    The Final FDII Regulations: Sales of Products to Foreign Customers for Foreign Use

    November 2020

    Read time: 1 min

    Key takeaways
    Overview

     

     

    In depth
    Authors

    Lowell D. Yoder

    Partner

    Chicago

    More insights

  • White House Bans Trading in 31 Chinese Companies

    White House Bans Trading in 31 Chinese Companies

    ARTICLE / CLIENT ALERT

    White House Bans Trading in 31 Chinese Companies

    November 13, 2020

    Read time: 2 min

    Key takeaways
    Overview

    On Nov. 12, 2020, President Donald Trump signed an Executive Order[1] that, effective Jan. 11, 2021, will impose a ban on trading by U.S. persons in the securities (and derivatives thereof) of 31 entities[2] deemed to be supporting the People’s Liberation Army of China (each, a “Covered Company,” a complete list of these companies is appended to this Alert). The Executive Order does not impose an immediate trading ban, and a temporary safe harbor is provided for divestment from Covered Companies.

    Timing and Effectiveness

    The Executive Order’s ban does not go into effect until early January. Furthermore, the Executive Order permits otherwise prohibited “purchases for value or sales,” through Nov. 11, 2021, if made “solely to divest” (wholly or partially) from Covered Companies.

    Authored by Brian T. Daly, Gary Stein, Betty Santangelo, Gregory L. Kinzelman, Hannah M. Thibideau and Joshua B. Wright.


    [1] See Executive Order on Addressing the Threat from Securities Investments that Finance Communist Chinese Military Companies (Nov. 12, 2020), available here.

    [2] See Qualifying Entities Prepared in Response to Section 1237 of the National Defense Authorization Act for Fiscal Year 1999 (PUBLIC LAW 105–261), Tranche 1, available here; and Tranche 2, available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    More insights

  • Unexplained Wealth Orders: Ground-Breaking Investigation Recovers Millions of Pounds Worth of Criminally Obtained Property

    Unexplained Wealth Orders: Ground-Breaking Investigation Recovers Millions of Pounds Worth of Criminally Obtained Property

    ARTICLE / CLIENT ALERT

    Unexplained Wealth Orders: Ground-Breaking Investigation Recovers Millions of Pounds Worth of Criminally Obtained Property

    November 12, 2020

    Read time: 5 min

    Key takeaways
    Overview

    In a landmark case last month, a businessman linked to notorious criminals surrendered £10 million in property, land, cash and other assets at the conclusion of an unexplained wealth order (UWO). This was the first successful prosecution where the UWO was granted because of the target’s association with others involved in serious domestic crime (rather than alleged foreign political corruption).

    In depth

    Unexplained Wealth Orders

    UWOs were introduced pursuant to the Criminal Finances Act (CFA) 2017 in order to bolster the United Kingdom’s proceeds of crime regime. In its 2017 Impact Assessment, the Home Office concluded that the size of the UK financial and professional services sector, the open economy and the attractiveness of the London property market to overseas investors made the United Kingdom unusually exposed to financial crime. It found the current anti-money-laundering legislation inadequate and considered that the new measures introduced by the CFA 2017 would enable law enforcement agencies to be increasingly effective in seizing the proceeds of crime.

    The UWO specifically was the government’s response to the difficulty in bringing civil recovery proceedings where there was little information about an individual’s source of wealth. The UWO places the onus on the subject of the order (the respondent) to explain the origin of assets that appear to be disproportionate to the respondent’s known lawful wealth.

    The High Court may grant a UWO in respect of any property if it is satisfied that:

    • There is reasonable cause to believe that the respondent holds the property (whether in entirety or in part with others) and that the value of the property is greater than £50,000.
    • There are reasonable grounds for suspecting that the known sources of the respondent’s lawfully obtained income would have been insufficient for the purposes of enabling the respondent to obtain the property.
    • The respondent is either a politically exposed person or there are reasonable grounds for suspecting that the respondent (or a person connected to the respondent) is, or has been, involved in serious crime (anywhere in the world).

    If a UWO is made, the respondent will be required to provide a statement setting out:

    • The nature and extent of their interest in the property
    • How they obtained the property (including how any related costs were met)
    • Other information in connection with the property as may be so specified.

    Businessman to Hand Over £10 Million at Conclusion of UWO

    The National Crime Agency (NCA) pursued Mansoor Mahmood Hussain after he appeared on the NCA’s radar during an investigation into organised crime in Leeds. Although he initially appeared to be a successful businessman with no previous convictions, investigations led the NCA to believe that he acted for notorious criminals, including a murderer and drug trafficker, and that he laundered their profits through a property empire.

    Whilst the NCA could not obtain the evidence required for charges of money laundering, it obtained a UWO from the High Court in July 2019, which compelled Mr Hussain to explain how his wealth had come from legitimate sources.

    By way of a sealed recovery order on 2 October 2020, the NCA reached a settlement agreement with Mr Hussain, which required him to hand over the vast majority of his assets, including almost £10 million in properties, assets and cash.

    This is the first time a UWO was obtained based solely on an individual’s alleged involvement with others connected to serious organised crime domestically (rather than foreign corruption) despite there being no convictions against the individual himself. As such, this case is a milestone demonstrating the power of UWOs and one that has significant implications for how the NCA will pursue illicit finance in the United Kingdom, by focusing on UK general crime in addition to overseas individuals linked to foreign regimes.

    It is also important to note that the prior UWOs granted were in respect of real property, whereas this case resulted in the surrender of personalty in addition to realty. Indeed, the law allows for a UWO to be granted in respect of money, real and personal property, things in action, and all other intangible or incorporeal property.

    We can expect to see the further use of UWOs in the future to address money laundering. That is a laudable goal, and money launderers should beware. However, one must always be concerned whenever dealing with such a powerful tool that the discretion to deploy it is exercised for its proper purposes and not in a discriminatory or politically motivated way. The United Kingdom is a long-established democracy, and there is great faith that prosecutorial discretion will be and is being exercised appropriately and is, in any event, subject to judicial review (indeed there has already been a successful judicial challenge against a UWO). Nevertheless, caution and careful monitoring of the use of UWOs is definitely the order of the day.

    Authors
    More insights

  • Top Ten Issues for Hospital Closures

    Top Ten Issues for Hospital Closures

    ARTICLE / CLIENT ALERT

    Top Ten Issues for Hospital Closures

    November 11, 2020

    Read time: 2 min

    Key takeaways
    Overview

    Ceasing hospital operations is a complex process that involves a range of critical planning and coordination steps to ensure the health, welfare and safety of hospital patients and mitigate legal and other risks for the hospital and its officers and directors. As hospitals and their governing bodies make tough decisions and prepare to cease operations, it is important to put in place comprehensive closure plans, and communicate details of these plans to stakeholders and regulatory bodies.

    Although not intended to be an exhaustive checklist, the following top ten issues should be considered as part of any closure process. To develop a final plan, each hospital should carefully review and consult with counsel on the impact of these considerations on the organization’s unique circumstances. Depending on the closure plan, this may require multiple sequential notices to regulators or others if, for example, the number of available beds are stepped down over a number of weeks or months, or where certain services are discontinued prior to the final shutdown.

    View the full checklist here.

    In depth
    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Kerrin B. Slattery

    Partner

    Chicago

    More insights

  • Short-time Work Can Make Restructurings More Difficult

    ARTICLE

    Short-time Work Can Make Restructurings More Difficult

    November 7, 2020

    Read time: 2 min

    Key takeaways
    Overview

    Since the beginning of the Covid 19 pandemic, short-time work has experienced an unparalleled renaissance, not least due to the campaigning of the German government. For numerous companies that were affected by the crisis, short-time work was often the means of choice to reduce personnel costs. The Federal Cabinet has now decided to extend the facilitations for short-time work introduced in response to the pandemic.

    In practice, however, the following question is being asked more often: what happens if short-time work is not enough to stabilise the company in the long term? The longer the crisis lasts, the more urgent it becomes for companies to deal with how to navigate the business in the future.

    Dr. Thomas Gennert explains the possible effects of short-time work and why this political instrument can even make restructurings more difficult.

    In depth
    Authors

    Dr. Thomas Gennert

    Partner

    Düsseldorf

    More insights

  • Commentary on the Decision of the German Federal Tax Supreme Court of 22 January 2020, II R 41/18

    ARTICLE

    Commentary on the Decision of the German Federal Tax Supreme Court of 22 January 2020, II R 41/18

    November 2020

    Read time: 2 min

    Key takeaways
    Overview

    The preferential treatment of business assets for inheritance and gift tax purposes is not applicable on so called young administrative assets that belong to the business for less than two years. It has been controversially discussed if the two years may include periods in which the administrative assets belonged to another corporate group entity. The Federal Tax Court decided on 22 January 2020 (file number II R 41/18) that in case of an upstream merger the two-year period for young administrative assets of the merged company begins anew following the merger.

    Dr. Nils Wighardt and Jonathan Storz published remarks on the decision and a statement regarding implications on the situation following the inheritance and gift tax reform 2016 in the tax journal DStZ 2020, p. 815 et seq.

    In depth
    Authors

    Jonathan Storz

    Counsel

    Munich

    More insights

  • Recording the Foreclosure Sale Deed—What’s the Fuss?

    ARTICLE

    Recording the Foreclosure Sale Deed—What’s the Fuss?

    November 9, 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Agencies Issue Final Employer Healthcare Price Transparency Rule

    Agencies Issue Final Employer Healthcare Price Transparency Rule

    ARTICLE / CLIENT ALERT

    Agencies Issue Final Employer Healthcare Price Transparency Rule

    November 9, 2020

    Read time: 9 min

    Key takeaways
    Overview

    On October 29, 2020, the US Departments of Health and Human Services, Labor and Treasury (collectively, the Departments) issued the Transparency in Coverage final rule (the Rule), along with a fact sheet, setting forth requirements for group health plans and health insurance issuers to disclose cost-sharing information upon request to participants, as well as additional pricing information to the general public. The Rule is the result of the president’s executive order on healthcare price transparency, issued in June 2019, and it follows the Hospital Price Transparency final rule, issued in November 2019. (For additional information, read our client alerts: “Executive Order on hospital price transparency may prompt disclosure of negotiated prices” and “CMS finalizes hospital price transparency requirements, disclosure of negotiated rates.”)

    The Rule requires most non-grandfathered group health plans and health insurance issuers to: (1) upon request, disclose pricing information specific to participants, beneficiaries or enrollees (or their authorized representative) (collectively referred to herein as participants); and (2) provide public disclosures in machine-readable files regarding in-network, out-of-network and prescription drug prices. This On the Subject summarizes some of the provisions of the Rule that apply to group health plan sponsors.

    In depth

    Required Public Disclosures

    The Rule mandates that for plan years that begin on or after January 1, 2022, group health plans must disclose online to the general public three separate files that include detailed pricing information.

    1. In-network machine-readable file must include:
      • For each coverage option, the name and 14-digit Health Insurance Oversight System (HIOS) identifier, or if unavailable, the 5-digit HIOS identifier, or if unavailable, the Employer Identification Number (EIN);
      • A billing code (in the case of prescription drugs, a National Drug Code (NDC)) and plain language description for each billing code for each covered item or service under each coverage option; and
      • All applicable rates (e., negotiated rates, underlying fee schedule rates or derived amounts) (i) reflected as dollar amounts; (ii) associated with the National Provider Identifier (NPI), Tax Identification Number (TIN) and Place of Service Code for each in-network provider; (iii) associated with the last date of the contract term or expiration date for each provider-specific applicable rate that applies to each covered item or service; and (iv) featuring a notation where a reimbursement arrangement other than a standard fee-for-service model (e.g., capitation or a bundled arrangement) applies.
    2. Out-of-network allowed amount machine-readable file must include:
      • For each coverage option, the name and 14-digit HIOS identifier, or if unavailable, the 5-digit HIOS identifier, or if unavailable, the EIN;
      • A billing code (in the case of prescription drugs, an NDC) and plain language description for each billing code for each covered item or service under each coverage option; and
      • Unique out-of-network allowed amounts and billed charges during the 90-day period beginning 180 days prior to publication of the file (to protect consumer privacy, data with fewer than 20 claims for payment must be excluded) (i) reflected as dollar amounts; and (ii) associated with the NPI, TIN and Place of Service Code for each out-of-network provider.
    3. Prescription drug machine-readable file must include:
      • For each coverage option, the name and 14-digit HIOS identifier, or if unavailable, the 5-digit HIOS identifier, or if unavailable, the Employer Identification Number (EIN);
      • The NDC, and the proprietary and nonproprietary name assigned to the NDC by the Food and Drug Administration for each prescription drug under each coverage option;
      • The negotiated rates (i) reflected as dollar amounts; (ii) associated with the NPI, TIN and Place of Service Code for each in-network provider; and (iii) associated with the last date of the contract term or expiration date for each provider-specific negotiated rate that applies to each NDC; and
      • Historical net prices (i) reflected as dollar amounts; (ii) associated with the NPI, TIN and Place of Service Code for each in-network provider; and (iii) associated with the 90-day period beginning 180 days prior to publication of the file for each provider-specific historical net price that applies to each NDC (to protect consumer privacy, data with fewer than 20 claims for payment must be excluded).

    The three files must be in a form and manner specified by the Departments and must be publicly available and accessible to any person free of charge and without conditions (e.g., establishing a user account or password), without the submission of personally identifiable information. Plans must update these three data files on a monthly basis and clearly indicate the date on which the files were updated.

    Required Participant Disclosures upon Request

    The Rule requires most group health plans to disclose information specific to a covered item or service to participants upon their request. For plan years that begin on or after January 1, 2023, group health plans must disclose the information below regarding an initial list of 500 services, as determined by the Departments. For plan years that begin on or after January 1, 2024, plans must disclose the information below regarding the remainder of all procedures, drugs, durable medical equipment and any other items or services.

    1. Estimate of the participant’s cost-sharing liability (e., deductibles, coinsurance and copayments) for a requested covered item or service;
    2. If the requested item or service is a recommended preventive service and the plan cannot determine whether the request is for preventive purposes, the cost-sharing liability that would apply for non-preventive services (or the participant may request cost-sharing information for the specific preventive or non-preventive item or service by including search terms such as “preventive,” “non-preventive” or “diagnostic”);
    3. Accumulated amounts that the participant previously incurred toward a deductible or out-of-pocket limit;
    4. In-network rate, including the following elements, if applicable to the plan:
      • Negotiated rate for an in-network provider for the requested covered item or service (even if this rate is not used to calculate cost-sharing liability); and
      • Underlying fee schedule rate for the requested covered item or service, if different than the negotiated rate;
    5. If the provider is an out-of-network provider, out-of-network allowed amount or any other rate that provides a more accurate estimate of the amount the plan will pay for the requested covered item or service;
    6. If the requested item or service is part of a bundled payment that includes items or services with separate cost-sharing liability, information regarding which items or services are included in the bundle for which cost-sharing information is provided;
    7. Notification of any applicable prerequisite to coverage;
    8. A notice that includes the following statements in plain language: (i) if balance billing is permitted, an out-of-network provider may bill the participant and the cost-sharing information does not include such amounts; (ii) the actual charges may vary from the provided estimates; (iii) the cost-sharing liability estimate is not a guarantee that benefits will be provided; (iv) whether the plan counts copayment assistance and other third-party payments in calculating the cost-sharing and out-of-pocket maximum; (v) preventive items may not be subject to cost-sharing liability; and (vi) any other information that the plan deems appropriate.

    Plans must make the foregoing disclosures available in plain language, without a fee, through an accurate self-service tool or website that allows participants to search for cost-sharing information by using: (i) a billing code or descriptive term; (ii) the name of an in-network provider, if applicable; and (iii) other relevant factors for determining cost-sharing information (e.g., location of service, facility name or dosage). Participants should be able to refine and reorder their search results based on proximity of in-network providers and the amount of estimated cost-sharing liability.

    At a participant’s request, the plan must make the foregoing disclosures available in plain language, without a fee, in paper form (in which case the disclosure may be limited to no fewer than 20 providers per request). The paper form must be mailed to the participant within two business days after receipt of the request. Alternatively, if the participant agrees, the plan may disclose the required information by phone or email.

    Group health plans are generally subject to the required public and participant disclosures, but insured plans may require their insurance issuer(s) to provide such disclosures. If such an arrangement is established pursuant to a written agreement, the issuer becomes liable for any violation of the public and participant disclosure requirements of the Rule. Any group health plan subject to the Rule, including self-funded plans, may contract with a third-party administrator to comply with the public and participant disclosures, but the Rule offers no liability shield for self-funded plans.

    Practical Application

    The Departments stated that in establishing the Rule, they aim to provide ample health insurance data for consumers, researchers and third parties to reduce healthcare costs and promote competition in the health insurance market. However, the Rule will likely receive legal challenges from health insurers arguing that it will undercut their ability to bargain with providers and drug companies. The Departments appear to have anticipated legal challenges to the Rule, as its preamble includes extensive legal justification, relying on legal authority under the Affordable Care Act (ACA). It is unclear how the Rule would survive if the ACA is partially or completely invalidated in ongoing litigation (e.g., California v. Texas).

    If the Rule withstands legal review, patients and their families could influence the health insurance market in an unprecedented way. To date, patients have often chosen providers based on reputation or recommendations. It remains to be seen how the Rule would affect patient choice, as the Rule does not require disclosure of any provider quality information.

    For most employer-sponsored group health plans, we predict that the Rule’s disclosure obligations would be met by third-party providers on behalf of a plan. Similar to when ACA reporting vendors began appearing, there will likely be a number of providers purporting to be able to meet these requirements but some will likely be better suited than others and some ill-equipped. Plan sponsors should exercise caution when contracting with these providers, to ensure both that they are able to meet the heavy demands of this Rule and that the plan and company are sufficiently indemnified and protected should the provider fall short.

    In the meantime, group health plan sponsors should monitor legal challenges to the Rule and prepare for the potentially significant burden of complying with the Rule’s public disclosure and participant disclosure requirements. For more information on whether and how these changes apply to your group health plan, please contact your regular McDermott employee benefits lawyer or one of the authors.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • Regulated Funds: SEC Adopts New Rule Governing the Use of Derivatives by Registered Investment Companies and BDCs

    Regulated Funds: SEC Adopts New Rule Governing the Use of Derivatives by Registered Investment Companies and BDCs

    ARTICLE / CLIENT ALERT

    Regulated Funds: SEC Adopts New Rule Governing the Use of Derivatives by Registered Investment Companies and BDCs

    November 9, 2020

    Read time: 18 min

    Key takeaways
    Overview

    On Oct. 28, 2020, the SEC voted to adopt new Rule 18f-4 under the Investment Company Act of 1940, as amended (“1940 Act”), to provide a modernized and comprehensive regulatory framework for the use of derivatives by regulated funds, including mutual funds (other than money market funds), exchange-traded funds (“ETFs”), registered closed-end funds and business development companies (“BDCs”) (collectively, “funds”).[1] Subject to various conditions, Rule 18f-4 will allow funds to enter into derivatives transactions, notwithstanding the restrictions on the issuance of “senior securities” and the use of leverage imposed by Sections 18 and 61 of the 1940 Act.[2]

    In connection with the adoption of Rule 18f-4, the SEC also amended Rule 6c-11 under the 1940 Act relating to leveraged/inverse ETFs and adopted new reporting requirements and amendments to certain disclosure forms. The new rule and related amendments will become effective 60 days after publication in the Federal Register, with a compliance date of 18 months after the effective date. Hedge funds and other private investment funds are not subject to the new rule or the related amendments.

    Overview of Rule 18f-4

    The key requirements of Rule 18f-4 are discussed in more detail below and include:

    • Adoption of a written derivatives risk management program containing risk guidelines and requiring stress testing, backtesting, internal reporting and escalation and program review;
    • Imposition of an outer limit on fund leverage risk, based either on a relative or absolute value-at-risk (“VaR”) test, comparing a fund’s VaR to the VaR of a “designated reference portfolio” for the fund; and
    • Designation of a derivatives risk manager who reports directly to the fund’s board of directors.

    Notably, Rule 18f-4 also provides an exception from these requirements for a fund that limits its derivatives exposure to 10% of its net assets (excluding derivatives transactions used to hedge certain currency and interest rate risks), provided that the fund establishes appropriate policies and procedures. In addition, leveraged/inverse funds, including ETFs, are subject to the Rule 18f-4 requirements, in a change from the rule as proposed.[3] In view of the significant number of comments received on the topic, the SEC did not adopt new sales practices rules that were proposed in connection with the Rule 18f-4 proposal that would have been applicable to sales of leveraged/inverse funds, but instead opted to make such funds subject to the requirements of the rule.[4] The new rule also permits a fund to enter into reverse repurchase agreements and “unfunded commitments,” subject to certain conditions. In particular, the rule clarifies that unfunded commitments will not count towards a fund’s asset coverage ratio under Sections 18 and 61 under the 1940 Act so long as the fund reasonably believes, at the time it enters into such a commitment, that it will have sufficient cash and cash equivalents to meet its obligations under such commitment when they come due. Lastly, funds (including money market funds) may invest in securities on a when-issued or forward-settling basis (or with a non-standard settlement cycle), subject to certain conditions.

    Background

    Generally, Section 18 of the 1940 Act restricts the issuance of “senior securities” by investment companies.[5] Section 18(g) defines a “senior security” as any bond, debenture, note or similar obligation constituting a security and evidencing indebtedness and any stock of a class having priority over any other class as to distribution of assets or payment of dividends (such as preferred stock). The SEC has interpreted this term broadly to include investment transactions and practices that create potential future obligations — generally, any transaction in which a fund has a potential future payment or delivery obligation, including certain derivatives transactions.

    The new rule represents a departure from guidance contained in an SEC release on the application of Section 18’s restrictions on certain investment practices (“Release 10666”),[6] as well as positions taken by the SEC staff in various no-action letters regarding transactions involving Section 18.[7] The SEC’s release adopting the rule (“Release”) notes the inconsistent industry practices that have developed in reliance on this guidance and acknowledges the need to replace the current patchwork approach to regulation of the use of derivatives in order to address investor protection concerns while also accommodating product innovation. In connection with the adoption of Rule 18f-4, the SEC is rescinding Release 10666 and the various no-action letters issued by the SEC staff.

    Scope of Derivatives Transactions Covered

    The rule defines a “derivatives transaction” to mean any swap, security-based swap, futures contract, forward contract, option, any combination of the foregoing, or any similar instrument under which a fund is or may be required to make any payment or delivery of cash or other assets during the life of the instrument or at maturity or early termination, whether as margin or settlement payment or otherwise, as well as any short sale borrowing and, if a fund chooses to rely on the rule, any reverse repurchase agreement or similar financing transaction.[8] This definition is intended to capture derivatives transactions that, in the SEC’s view, involve the issuance of a senior security (i.e., transactions that create a potential future payment or delivery obligation).[9] Instruments that may commonly be referred to as derivatives, but which do not create a potential future payment or delivery obligation (e.g., purchased options and structured notes), fall outside of this definition.

    Derivatives Risk Management Program and Board Oversight

    Under Rule 18f-4, a fund using derivatives that does not otherwise qualify as a “limited derivatives user” will be required to implement a written derivatives risk management program (“Program”) administered by a derivatives risk manager and overseen by the fund’s board of directors (“Board”). The Release notes that the Program should be a part of an adviser’s overall risk management and should complement other risk management activities, such as a fund’s liquidity risk management program under Rule 22e-4.[10] The Program must be tailored to the fund’s use of derivatives and also must include appropriate risk guidelines, along with requirements for stress testing, backtesting, internal reporting and escalation and periodic review of the Program. The risk guidelines must provide for quantitative thresholds of the fund’s derivatives risks, and must specify the levels that a fund does not normally expect to exceed. Stress testing must be undertaken on at least a weekly basis, and the rule also requires backtesting of the results of the VaR calculation model used by the fund in connection with the VaR tests described in more detail below.

    A Program must be administered by a derivatives risk manager, comprised of an officer or officers of the fund’s investment adviser having relevant experience regarding the management of derivatives risk.[11] The derivatives risk manager may not be a portfolio manager of the fund, unless multiple individuals serve together, in which case portfolio managers may serve if they do not represent a majority of the individuals serving. The designation of the derivatives risk manager must be approved by the Board and the risk manager must periodically review the Program at least annually and provide a written report to the Board on the effectiveness of the Program also at least annually. The risk manager must also provide regular written reports to the Board at a frequency determined by the Board. However, under the rule the Board is not required to make any particular findings and the Board does not need to receive a report on every exceedance of the Program’s guidelines, but instead must receive an analysis of exceedances that occurred during the period covered by the report.

    VaR Limits on Fund Leverage Risk

    A core component of Rule 18f-4 is the outer limit placed on fund leverage risk based on VaR, which is a statistical measurement used to calculate probable losses on an investment. As defined in the rule, VaR is an estimate of an instrument’s or portfolio’s potential losses over a specified time horizon and at a given confidence level.[12] VaR can help assess the impact of derivatives use on a fund’s portfolio, including whether such transactions are being used to leverage the fund’s portfolio or instead to hedge portfolio investments.

    A fund that relies on the rule when engaging in derivatives transactions that does not otherwise qualify as a “limited derivatives user” thereunder must compare the fund’s VaR to the VaR of a “designated reference portfolio” or, if that is determined not to be appropriate, must use an absolute VaR test. As adopted, the “designated reference portfolio” used in the relative VaR test either can be an index meeting certain requirements specified in the rule or the fund’s own securities portfolio (excluding derivatives transactions). Under the proposed rule, only an index was permissible for VaR comparison purposes.

    Under the relative test, a fund’s VaR generally must not exceed 200% of the designated reference portfolio’s VaR and under the absolute test it must not exceed 20%. This represents an increase from the threshold as proposed, from 150% as proposed for the relative test and from 15% as proposed for the absolute test.[13]

    Limited Derivatives Users

    Under the rule, a fund with derivatives exposure of no more than 10% of its net assets (excluding certain currency and interest rate hedging transactions) will not need to comply with the VaR testing requirements or the requirement to implement a derivatives risk management program. Instead, it must adopt policies and procedures reasonably designed to manage its derivatives risk. In order to qualify for exclusion from the above calculation, derivatives that hedge currency or interest rate risks must be associated with one or more specific equity or fixed-income investments held by the fund or the fund’s outstanding borrowings, must be entered into and maintained for hedging purposes, and must have notional amounts that do not exceed the value, par value or principal amount, as applicable, of the hedged investment or borrowing by more than 10%.

    Leveraged/Inverse Funds

    As noted above, the SEC determined not to adopt the sales practices rules included in the proposed rule that would have applied to broker-dealers and investments advisers selling leveraged/inverse funds. Instead, leveraged/inverse funds using derivatives are subject to Rule 18f-4, as adopted, and are required to use an index as their designated reference portfolio. The Release notes that certain of the investor protection concerns underlying the proposed sales practices rules are addressed by the best interest standard of conduct for broker-dealers under Regulation Best Interest, and that investment advisers are subject to fiduciary obligations in the context of advisory agreements. However, the SEC states in the Release that it has directed its staff to consider any additional requirements that should apply to broker-dealers and investment advisers in order to protect investors who invest in leveraged/inverse products and other complex investment products.

    In connection with leveraged/inverse ETFs, the SEC also amended Rule 6c-11 to include such ETFs within the scope of that rule, provided that they comply with Rule 18f-4, as applicable. Rule 6c-11 allows sponsors of ETFs to launch and operate ETFs without first obtaining individual exemptive orders from the SEC, subject to satisfying certain conditions.[14] Additionally, all past exemptive orders issued to leveraged/inverse ETFs are rescinded.

    Reverse Repurchase Agreements

    Under Rule 18f-4, a fund can engage in reverse repurchase agreements and similar financing transactions, either by meeting the asset coverage requirements of Section 18 or by electing to treat such transactions as derivatives and meeting the requirements of the rule. As a result, funds will going forward have an alternate path under the rule for utilizing reverse repurchase agreements and similar financing structures. Funds that do not otherwise engage in derivative transactions thus may have a greater ability to utilize reverse repurchase agreements in reliance on the rule than they would enjoy by treating such financing arrangements as senior securities under Section 18.

    Unfunded Commitments

    The rule also clarifies the previously vague treatment of unfunded commitments under Sections 18 and 61 of the 1940 Act. In particular, the rule explicitly permits a fund to enter into an unfunded commitment agreement to make certain loans or investments, notwithstanding the requirements of Sections 18 and 61, if the fund reasonably believes that it will have sufficient cash and cash equivalents to meet its obligations as they come due. As a result, funds that directly originate new portfolio investments, including most notable BDCs and other credit-focused funds, will no longer be required to consider unfunded commitments to existing portfolio companies when determining compliance with applicable leverage ratios under Sections 18 and 61, so long as they meet the requirements of the rule with respect to those commitment agreements.

    Amendments to Fund Reporting Requirements

    In connection with Rule 18f-4, the SEC is adopting amendments to the reporting requirements for funds relying on the rule in Forms N-PORT, N-CEN and N-LIQUID (which will be renamed N-RN). The amendments are intended to allow the SEC to oversee funds’ use of derivatives and to provide information on derivatives use to the SEC, investors and other market participants.

    The amendment to Form N-PORT will add new reporting items requiring information about VaR testing (specifically, information on median VaR and median VaR ratio and the number of exceptions identified during backtesting) and will require funds relying on the limited derivatives user exception to report their derivatives exposure, along with the number of business days, if any, the fund’s derivatives exposure exceeded 10% of its net assets. Such information will be confidentially reported to the SEC and will not be publicly disclosed. Information about the fund’s designated reference portfolio will also be required to be disclosed on the form and will be made publicly available.

    As noted above, Form N-LIQUID will be renamed Form N-RN and will be amended to require that funds report information about breaches of the relative or absolute VaR tests within one business day following the fifth business day after the fund has determined its portfolio VaR has exceeded the relevant thresholds. A second report on Form N-RN will be required once the fund is back in compliance with the VaR test. While only open-end funds (excluding money market funds) are currently required to file reports on Form N-LIQUID, all funds subject to the Rule 18f-4 limits will be required to file on Form N-RN. Reporting relating to VaR made on Form N-RN will be non-public.

    Form N-CEN is being amended to require funds to identify whether they relied on Rule 18f-4 during the reporting period, as well as if any exceptions under the rule were relied upon. Funds will also be required to identify whether they have entered into any reverse repurchase agreements or similar financing transactions or any unfunded commitments pursuant to Rule 18f-4.

    Recordkeeping Requirements

    Under the rule, a fund will be required to maintain a written record of its policies and procedures that are designed to manage the fund’s derivatives risk, along with written records of the results of stress testing, backtesting, internal reporting or escalation of material risks under the derivatives risk management program and any periodic reviews of the Program. The rule also requires that a fund maintain records of written reports provided to its Board relating to the Program, as well as any reports to the Board regarding a fund’s non-compliance with a VaR test. In addition, within 30 calendar days of any exceedance of a VaR test, a fund’s derivatives risk manager must provide a written report to the Board with details on the exceedance. Among other things, funds will also have to maintain records documenting other relevant information regarding calculation of VaR and limited derivatives users must maintain written records of their policies and procedures that are reasonably designed to manage derivatives risk. Required records must be maintained for a period of five years.

    Key Takeaways

    Rule 18f-4 provides regulated funds that engage in derivatives transactions with a prescribed framework for compliance with the requirements of Section 18 (or Section 61 in the case of BDCs). However, the rule represents a significant departure from existing regulatory guidance established by Release 10666 and various SEC staff no-action letters. Investment advisers should assess how their funds will comply with the new rule and whether the funds’ investment strategies must be altered to achieve compliance. In particular, for those funds that qualify as limited derivatives users, the impact of the rule will likely be far less than for those that utilize derivatives instruments more routinely. Notably, we expect the limited derivatives user exception to likely be meaningful, particularly for funds focused on credit investments or with significant offshore exposures, given the carve-out for certain currency and interest rate hedging transactions when determining availability of the exception under the rule.

    Particularly for those funds that fall outside the scope of the limited derivatives user exception, operational burdens of the rule and the derivatives risk management program, including the anticipated costs of compliance should be considered. Fund boards should be engaged in this process and should assure their familiarity with their funds’ practices with respect to the use of derivatives and the process for monitoring associated risks. For funds that are subject to full compliance with the requirements under the rule, boards will have new responsibilities, including appointing a derivatives risk manager and reviewing periodic reports on the risk management program. The rule may also affect to varying degrees the investment practices of funds that engage in derivatives transactions, particularly if they fail to qualify as limited derivatives users under the rule. As a result of the increased regulatory burdens imposed under the rule, we also expect some funds will seek to limit or reduce their usage of derivatives instruments to ensure they remain within the limited derivatives user exception.  

    We expect the treatment of both reverse repurchase agreements and unfunded commitment agreements under the rule also to have a potentially meaningful impact on a more narrow subset of funds. In particular, funds that have historically utilized reverse repurchase agreements for short-term financing purposes may seek to expand their usage by treating such instruments as derivatives instruments under the rule. In addition, BDCs and other direct-lending funds will likely benefit from the regulatory clarity provided under the rule with respect to the treatment of unfunded commitment agreements under Sections 18 and 61 under the 1940 Act.

    Authored by Craig Stein, Atul Joshi and Karen Spiegel.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Use of Derivatives by Registered Investment Companies and Business Development Companies, Investment Company Act Release No. 34078 (Oct. 28, 2020), https://www.sec.gov/rules/final/2020/ic-34078.pdf. The SEC’s press release No. 2020-269, https://www.sec.gov/news/press-release/2020-269.  The proposed rule and request for comments, https://www.sec.gov/rules/proposed/2019/34-87607.pdf.

    [2] The rulemaking represents a re-proposal of rules that were initially proposed in 2015. See Use of Derivatives by Registered Investment Companies and Business Development Companies, Investment Company Act Release No. 31933 (Dec. 11, 2015), https://www.sec.gov/rules/proposed/2015/ic-31933.pdf.  In addition, in 2011, the SEC issued a concept release soliciting comments on various issues associated with the use of derivatives by registered investment companies.  See Use of Derivatives by Investment Companies under the Investment Company Act of 1940, Investment Company Act Release No. 29776 (Aug. 31, 2011), https://www.sec.gov/rules/concept/2011/ic-29776.pdf.

    [3] As defined by the rule, a leveraged/inverse fund is a fund that seeks to provide investment returns that correspond to the performance of a market index by a specified multiple, or to provide investment returns that have an inverse relationship to the performance of a market index, over a predetermined time. Leveraged/inverse funds in operation as of Oct. 28, 2020 are excepted from the VaR limits of the rule, subject to various conditions.

    [4] The SEC received over 6,000 comment letters addressing the proposed sales practices rules.

    [5] Section 61 of the 1940 Act makes Section 18 applicable to business development companies, with certain modifications.

    [6] Securities Trading Practices of Registered Investment Companies, Investment Company Act Release No. 10666 (Apr. 18, 1979).

    [7] See, e.g., Dreyfus Strategic Income (pub. avail. June 22, 1987), Robertson Stephens Investment Trust (pub. avail. Aug. 24, 1995) and Merrill Lynch Asset Management, L.P. (pub. avail. July 1, 1996). 

    [8] Proposed Rule 18f-4(a). The rule allows funds to elect to treat reverse repurchase agreements and similar financing transactions as derivatives transactions subject to the rule, or to choose to be subject to the asset coverage requirements of Section 18.

    [9] Release at 21.

    [10] However, unlike the liquidity risk management program required by Rule 22e-4, a derivatives risk management program does not have to be approved by the Board. See “Registered Investment Company Update: New Guidance on Liquidity Risk Management Programs,” SRZ Alert (Feb. 7, 2018), /insights/registered-investment-company-update-new-guidance-on-liquidity/.

    [11] The Release acknowledges that an individual who is not technically an officer of the investment adviser may have the requisite seniority and experience to carry out the role of derivatives risk manager, and if approved by the Board, such person can be treated as an officer for purposes of the rule. In addition, while the rule permits officers of a fund’s sub-adviser to serve as part of the group comprising a fund’s derivatives risk manager, the Release notes that certain elements of the Program may not be delegated to a sub-adviser managing only a portion of the assets of the fund, given that elements of the Program such as stress testing must be evaluated at the portfolio level.

    [12] Rule 18f-4 requires that any VaR model used for purposes of compliance with the rule: (1) take into account and incorporate all significant, identifiable market risk factors associated with a fund’s investments, including, as applicable: (i) equity price risk, interest rate risk, credit spread risk, foreign currency risk and commodity price risk; (ii) material risks arising from the nonlinear price characteristics of a fund’s investments, including options and positions with embedded optionality; and (iii) the sensitivity of the market value of the fund’s investments to changes in volatility; (2) use a 99% confidence level and a time horizon of 20 trading days; and (3) be based on at least three years of historical market data.

    [13] For closed-end funds that have outstanding shares of a senior security that is a stock, the relative and absolute VaR limits are 250% and 25%, respectively.

    [14] Exchange-Traded Funds, Investment Company Release No. 33646 (Sept. 25, 2019), https://www.sec.gov/rules/final/2019/33-10695.pdf. See “New SEC Rule Aims to Streamline ETF Regulation,” SRZ Alert (Oct. 17, 2019), /insights/new-sec-rule-aims-to-streamline-etf-regulation/.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • Cookie Trade Dress Infringement Case Crumbles in Face of Functionality Challenge

    Cookie Trade Dress Infringement Case Crumbles in Face of Functionality Challenge

    ARTICLE

    Cookie Trade Dress Infringement Case Crumbles in Face of Functionality Challenge

    November 5, 2020

    Read time: 1 min

    Key takeaways
    Overview

     

     

    In depth
    Authors

    Eleanor B. Atkins

    Partner

    Washington, DC

    More insights